SCHEMBL31023951

SCHEMBL31023951

Cn1ncc2cc(C(=C3CCN(C(=O)n4cnc(C#N)n4)CC3)c3ccc4c(cnn4C)c3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 1/20 0.40
▸ TNKS O95271 1/20 0.39
▸ TNKS2 Q9H2K2 1/20 0.39
▸ KDM2B Q8NHM5 1/20 0.39
▸ KDM1A O60341 5/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ CREBBP Q92793 1/20 0.37
▸ MAOB P27338 3/20 0.36
▸ MAOA P21397 2/20 0.36
▸ ACHE P22303 1/20 0.36
▸ USP30 Q70CQ3 2/20 0.36
▸ VNN1 O95497 1/20 0.36
▸ PTGER3 P43115 1/20 0.35
▸ WNT1 P04628 1/20 0.35
▸ CLK2 P49760 1/20 0.35
▸ CLK3 P49761 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ CACNA1H O95180 2/20 0.34
▸ ESR1 P03372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023919 0.80 MGLL (0.54) MGLLKDM1ABRD4CREBBPUSP30
SCHEMBL31023858 0.73 MGLL (0.50) MGLL
SCHEMBL31023871 0.72 FAAH (0.48) MGLL
SCHEMBL31023890 0.71 MGLL (0.48) MGLL
SCHEMBL31023710 0.70 MAOB (0.43) TNKSTNKS2KDM2BKDM1AMAOB
SCHEMBL4410330 0.64 MAOB (0.59) KDM2BMAOBMAOAACHEVNN1
SCHEMBL1144709 0.64 MAOB (0.56) TNKSTNKS2KDM2BMAOBMAOA
SCHEMBL30159516 0.64 MAOB (0.56) TNKSTNKS2KDM2BMAOBMAOA
SCHEMBL15875020 0.63 AR (0.66) KDM2BBRD4MAOBMAOAACHE
SCHEMBL30159522 0.63 AR (0.66) KDM2BBRD4MAOBMAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 — — EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 — — US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL MGLL 1/4885TNKS 4386/4885TNKS2 4270/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL MGLL 1/4885TNKS 4386/4885TNKS2 4270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback